Write your message
Volume 7, Issue 5 (September - October 2022)                   J Obstet Gynecol Cancer Res 2022, 7(5): 414-421 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bouzari Z, Mohammadi T, Ranaei M, Hajian-Taliki K, Ghanbarpour A. Association Between Gestational Diabetes History with Endometrial Hyperplasia and Cancer. J Obstet Gynecol Cancer Res. 2022; 7 (5) :414-421
URL: http://jogcr.com/article-1-555-en.html
1- Infertility and Reproductive Health Research Center, Health Research Institute and Department of Obstetrics and Gynecology, Babol University of Medical Sciences, Babol, Iran
2- Student Committee Research, Babol University of Medical Sciences, Babol, Iran
3- Clinical Research Development Unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
4- Infertility and Reproductive Health Research Center, Health Research Institute and Department of Obstetrics and Gynecology, Babol University of Medical Sciences, Babol, Iran , dr_ghanbarpour@yahoo.com
Abstract:   (112 Views)

Background & Objective: Gestational diabetes mellitus (GDM) is also defined as a metabolic disease associated with relative insulin resistance during pregnancy, and elevated circulating insulin may increase the risk of EH and EC development. This study aimed to investigate the association between GDM and the incidence of EH and EC.
Materials & Methods: We conducted a retrospective case-control study, including 300 women with abnormal uterine bleeding (AUB) referred to Ayatollah Rouhani Hospital in Babol. Cases (n=152) were patients with HC and EC based on medical records, and the controls (n=148) were individuals without HC and EC. The groups were compared according to demographic information, GDM or diabetes mellitus (DM) history, and body mass index (BMI). The Chi-square, independent t-test, and logistic regression analyses were performed to compare groups.
Results: Of 300 women studied, 72 people (24.1%) had a GDM history, and 64 people had a diabetes mellitus history. There was a significant difference between the incidence of EC and EH with GDM (P=0.001). Both GDM and DM were associated with the increased EC (OR: 17.98, 95% CI: 6.73-48.08, and OR: 1.84, 95% CI: 1.26-2.68, respectively). GDM was also associated with the increased risk of EH (OR: 6.68, 95% CI: 2.77-16.10), whereas diabetes mellitus had not a significant role in the increased risk of EH (P=0.14).
Conclusion: This study indicated that a GDM history is significantly associated with HC and EC. Therefore, to prevent and control these two complications in the future, management and monitoring of diabetes during pregnancy should be considered.

Full-Text [PDF 686 kb]   (26 Downloads) |   |   Full-Text (HTML)  (12 Views)  
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2021/11/21 | Accepted: 2022/02/5 | Published: 2022/07/7

1. Sidorkiewicz I, Jóźwik M, Niemira M, Krętowski A. Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA. Cancers. 2020;12(9):2559. [DOI:10.3390/cancers12092559] [PMID] [PMCID]
2. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y-B, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607. [DOI:10.1200/JCO.2012.48.2596] [PMID] [PMCID]
3. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232-54. [DOI:10.1093/humupd/dmw042] [PMID] [PMCID]
4. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a new designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. J Biomol Struct Dyn. 2016;34(5):1123-31. [DOI:10.1080/07391102.2015.1071280] [PMID]
5. Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, et al. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2016;140(1):184-90. [DOI:10.1016/j.ygyno.2015.10.020] [PMID] [PMCID]
6. Busch EL, Crous-Bou M, Prescott J, Chen MM, Downing MJ, Rosner BA, et al. Endometrial cancer risk factors, hormone receptors, and mortality prediction. Cancer Epidemiol Biomark Prev. 2017;26(5):727-35. [DOI:10.1158/1055-9965.EPI-16-0821] [PMID] [PMCID]
7. Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, et al. Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1081-9. [DOI:10.1158/1055-9965.EPI-16-0225] [PMID] [PMCID]
8. Zeng X, Xie Y-j, Liu Y-t, Long S-l, Mo Z-c. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. [DOI:10.1016/j.cca.2019.11.003] [PMID]
9. Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. J Biomol Struct. 2020;38(2):609-15. [DOI:10.1080/07391102.2019.1581088] [PMID]
10. Lai Y, Sun C. Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. Oncol Lett. 2018;15(2):2173-8. [DOI:10.3892/ol.2017.7590]
11. Sivalingam VN, Kitson S, MacKintosh ML, Rutter MK, Crosbie EJ. Interventions to improve insulin resistance for the prevention of endometrial cancer. Cochrane Database Syst Rev. 2020;2020(1):CD013523. [DOI:10.1002/14651858.CD013523] [PMCID]
12. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019;5(1):1-19. [DOI:10.1038/s41572-019-0098-8] [PMID]
13. Zare Z, Dizaj TN, Lohrasbi A, Sheikhalishahi ZS, Asadi A, Zakeri M, et al. Silibinin inhibits TGF-β-induced MMP-2 and MMP-9 through Smad Signaling pathway in colorectal cancer HT-29 cells. Clin Cancer Res. 2020;12(2):79-88. [DOI:10.18502/bccr.v12i2.5752]
14. Wartko PD, Beck TL, Reed SD, Mueller BA, Hawes SE. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes & Control. 2017;28(8):819-28. [DOI:10.1007/s10552-017-0908-9] [PMID] [PMCID]
15. Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018;29(11):743-54. [DOI:10.1016/j.tem.2018.09.004] [PMID]
16. Shafaei Z, Abazari O, Divsalar A, Ghalandari B, Poursoleiman A, Saboury AA, et al. Effect of a Synthesized Amyl-Glycine1, 10-Phenanthroline Platinum Nitrate on Structure and Stability of Human Blood Carrier Protein, Albumin: Spectroscopic and Modeling Approaches. J Fluoresc. 2017;27(5):1829-38. [DOI:10.1007/s10895-017-2120-4] [PMID]
17. Wartko PD. Association of endometrial hyperplasia or cancer with a history of gestational diabetes-results from a population-based study in Washington State, 1987-2013 2015.
18. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094-108. [DOI:10.1016/S0140-6736(15)00130-0] [DOI:10.1016/S0140-6736(15)00130-0]
19. Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98(9):1086-99. [DOI:10.1111/aogs.13587] [PMID]
20. Gompel A. Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020. [DOI:10.1016/j.bpobgyn.2020.05.003] [PMID] [DOI:10.1016/j.bpobgyn.2020.05.003] [PMID]
21. Braun MM, Overbeek-Wager E, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468-74.
22. Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet. 2019;299(5):1233-42. [DOI:10.1007/s00404-019-05103-1] [PMID]
23. Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro‐inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. Iran J Allergy Asthma Immunol. 2019:1-10. [DOI:10.18502/ijaai.v19i1.2421]
24. Kampmann U, Madsen LR, Skajaa GO, Iversen DS, Moeller N, Ovesen P. Gestational diabetes: a clinical update. World J Diabetes. 2015;6(8):1065. [DOI:10.4239/wjd.v6.i8.1065] [PMID] [PMCID]
25. Peng Y-S, Lin J-R, Cheng B-H, Ho C, Lin Y-H, Shen C-H, et al. incidence and relative risk for developing cancers in women with gestational diabetes mellitus: a nationwide cohort study in Taiwan. BMJ open. 2019;9(2):e024583. [DOI:10.1136/bmjopen-2018-024583] [PMID] [PMCID]
26. Saed L, Varse F, Baradaran HR, Moradi Y, Khateri S, Friberg E, et al. The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis. BMC cancer. 2019;19(1):527. [DOI:10.1186/s12885-019-5748-4] [PMID] [PMCID]
27. Lucenteforte E, Bosetti C, Talamini R, Montella M, Zucchetto A, Pelucchi C, et al. diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. British journal of cancer. 2007;97(7):995-8. [DOI:10.1038/sj.bjc.6603933] [PMID] [PMCID]
28. Ott R, Melchior K, Stupin JH, Ziska T, Schellong K, Henrich W, et al. Reduced insulin receptor expression and altered DNA methylation in fat tissues and blood of women with GDM and offspring. J Clin Endocrinol Metab. 2019;104(1):137-49. [DOI:10.1210/jc.2018-01659] [PMID]
29. Musavi H, Abazari O, Barartabar Z, Kalaki-Jouybari F, Hemmati-Dinarvand M, Esmaeili P, et al. The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms. Arch Physiol Biochem. 2020:1-9. [DOI:10.1080/13813455.2020.1826530] [PMID]
30. Piltonen TT. Polycystic ovary syndrome: endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016;37:66-79. [DOI:10.1016/j.bpobgyn.2016.03.008] [PMID]
31. Tian W, Teng F, Zhao J, Gao J, Gao C, Sun D, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression. Cancer Biol Ther. 2017;18(12):1000-10. [DOI:10.1080/15384047.2017.1394547] [PMID] [PMCID]
32. Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, et al. Regulation of insulin like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett. 2014;8(5):1993-9. [DOI:10.3892/ol.2014.2466] [PMID] [PMCID]
33. Tian W, Teng F, Gao J, Gao C, Liu G, Zhang Y, et al. Estrogen and insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways. Cancer Biol Med. 2019;16(1):55. [DOI:10.20892/j.issn.2095-3941.2018.0157] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.